SpectRx Inc. of Norcross, Ga., has received a fifth grant worth $690,000 from the National Cancer Institute (NCI) in Bethesda, Md. The company has been awarded a total of $3.2 million in NCI funding to finance an ongoing FDA trial of its noninvasive cervical cancer detection device, which measures light reflected from the cervix and which produces a diagnostic image. The trial is expected to be finished in 2007.